C-11 choline PET/CT boosts early prostate ca detection

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 11
Volume 18
Issue 11

Findings of a study by researchers in Italy suggest C-11 choline PET/CT could diagnose prostate cancer recurrence sooner than transrectal ultrasound, CT, MRI, or bone scintigraphy in patients who have undergone radical prostatectomy.

Findings of a study by researchers in Italy suggest C-11 choline PET/CT could diagnose prostate cancer recurrence sooner than transrectal ultrasound, CT, MRI, or bone scintigraphy in patients who have undergone radical prostatectomy.

Up to 30% of patients with prostate cancer who have undergone radical prostatectomy will relapse within 10 years. The statistics are more discouraging for those treated with external-beam radiotherapy, as more than half will experience some form of recurrence within five years.

According to a research group from the University of Bologna led by Paolo Castellucci, MD, PET/CT with C-11 choline has emerged as a promising alternative.

“In most patients with biochemical relapse after radical prostatectomy, conventional imaging methods often return false-negative results,” Dr. Castellucci said. “Our study found that for some patients, PET/CT with choline can improve the detection of cancer soon after PSA levels are measured.”

The group retrospectively evaluated 190 patients with biochemical relapse after radical prostatectomy who underwent C-11 choline PET/CT. Patients were classified by PSA levels as well as PSA kinetic factors such as PSA velocity and PSA doubling time.

The investigators found that detection of cancer recurrence with whole-body choline PET/CT in patients with biochemical relapse after prostatectomy correlates significantly with PSA levels and PSA kinetics, particularly in patients with low PSA levels (J Nucl Med 50:1394-1400, 2009).

Although further studies are needed, C-11 choline PET/CT has the potential to become a one-stop test to identify patients with early relapse who have the best chances for curative treatment and recovery, the investigators wrote.

Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Related Content